Plant-Based Natural Products for Breast Cancer Prevention: A South Asian Association for Regional Cooperation (SAARC) Countries Perspective

Badrul Alam1, Ahsan Javed1, Alshammari Fanar1, Hee-Jeong Choi2 and Sang-Han Lee1*
1School of Food Science and Biotechnology, Graduate School, Kyungpook National University, Korea
2Food and Bio-Industry Research Institute, Kyungpook National University, Korea

Abstract

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths among women worldwide. Chemotherapeutic drugs have yielded limited anticancer activity and have not reduced the high recurrence rate. This has fueled efforts into the identification of more effective anticancer agents. A focus on natural products with potential anticancer activity exhibiting less adverse effects has led to the study of medicinal plants. This has resulted in the discovery of compounds with remarkable chemical structures exhibiting diverse biological activities. Geography and climate variations between the South Asian Association for Regional Cooperation (SAARC) countries have provided an array of environmental conditions that yield versatile plant species. These may be used for the preparation of traditional medicine and have attracted significant attention from the scientific community. In this review, we focus on the anticancer properties of twenty-five medicinal plant species and their active constituents, which grow in SAARC countries including India, Bangladesh, Pakistan, Nepal, Sri Lanka, Bhutan, the Maldives, and Afghanistan. The mechanisms of action associated with these compounds provide a glimpse of the current trends driving anticancer drug discovery, especially with respect to breast cancer.

Keywords: Plant; Breast cancer; Prevention; South Asian Association for Regional Cooperation (SAARC)

Introduction

Cancer is a significant healthcare issue that affects two-thirds of the global population and is the second most common cause of death worldwide. Only modest progress has been made in reducing the morbidity and mortality of this group of diseases [1]. Breast cancer is the most common cancer in women, both in developing and developed countries. According to the GLOBOCAN estimate, more than half (52.9%) of the 1.67 million new breast cancer cases were diagnosed in developing countries in 2012, whereas the corresponding figure in 1980 was only 35% [2]. In South Asia, approximately 588 million women over the age of 15 are experiencing a growing breast cancer epidemic [3]. In 2012, an estimated 200,000 new breast cancer cases have occurred in South Asia and approximately 975,000 women have died of this disease [2]. Despite current efforts to promote health, an increased lifespan in developing countries resulting from efficient management of infectious diseases and increased adaptation of a Western lifestyle are considered risk factors for breast cancer [4]. Chemoprevention, by definition, is a means of controlling cancer by administering one or more naturally occurring and/or synthetic agents to entirely prevent, slow, or reverse cancer occurrence or its development. This concept has gained increased attention, in part, because of its cost-effectiveness. An increased understanding of the epigenetic, genetic, molecular, cellular, and developmental characteristics of cancer has created opportunities to disrupt and reverse the initiation and progression of this disease. Additionally, these advances have identified physiological and pharmacologic mechanisms for therapeutic intervention aimed at preventing end-stage, invasive disease or delaying cancer development [5].

According to the WHO, more than 80% of the world’s population depends on traditional medicine for their primary healthcare needs [6]. Plants represent a rich source of medicinal compounds and more than half of the currently available drugs are natural compounds or derivatives of such compounds. Over 60% of the currently used anticancer agents are derived from natural sources [7]. The anticancer effects of these natural products target inflammatory processes and...
oncogenic transformation, including alterations in cell cycle control, apoptosis evasion, angiogenesis, and metastasis [8].

Geography and climate variations among the South Asian Association for Regional Cooperation (SAARC) countries provides a plethora of environmental conditions for the growth of versatile plant species that may be used for the preparation of traditional medicines and has drawn significant interest from the scientific community. In this review, we focus on the anticancer potential of medicinal plant species and their active constituents, particularly against breast cancer, which are commonly grown in SAARC countries including India, Bangladesh, Pakistan, Nepal, Sri Lanka, Bhutan, the Maldives, and Afghanistan.

**Breast Cancer and Its Signaling Pathways**

Breast cancer is hallmarked by the uncontrolled growth of cells to form a solid lump or tumor in the lobules (milk-producing glands) or ducts (the passages that carry milk to the nipples) of breast tissue. These cells may start disseminating into the blood and lymphatic systems even at early stages or when the tumor size is small [9].

The underlying mechanisms associated with individual breast cancer subtypes are complex and their corresponding gene expression profiles are dependent on various oncogenic pathways. The maintenance and differentiation of normal breast tissue are controlled by signaling pathways that involve cytokines, chemokines, growth factors, steroid hormones, adhesion molecules, and their associated receptors. Attenuation of these pathways by single or multiple components of the tumor microenvironment has been implicated in the promotion, growth invasion, and metastasis of breast cancer [10]. Advances in our understanding of the etiology, biology, and signaling systems involved in the development and survival of breast cancer have identified putative targets that may be exploited in the development of new agents for breast cancer treatment.

The epidermal growth factor receptor (EGFR or HER-2) family consists of cell surface tyrosine kinase receptors that are involved in the regulation of cell proliferation, differentiation, and survival in breast cancer. Each HER receptor contains an extracellular domain involved in ligand binding and an intracellular domain that exhibits tyrosine kinase activity. Upon ligand binding, the extracellular domain of the receptors undergoes a conformational change resulting in the phosphorylation of the intracellular tyrosine kinase domain. This leads to the activation of multiple signaling pathways that promote proliferation and survival, including the PI3K/Akt/mTOR, Erk1/2MAPK, and JAK/STAT pathways [11,12]. A similar scenario occurs for HER2 in which activation occurs in a ligand-independent manner, predominantly when the receptor is overexpressed or mutated [13]. Constitutive activation of growth factor signaling pathways resulting from the overexpression of HER2 serves as an oncogenic driver in breast cancer. Herceptin, also known as trastuzumab, is a humanized recombinant monoclonal antibody that attaches to the extracellular domain of HER2 and ultimately exerts a selective anticancer effect. For over a decade, the drug has dramatically altered the response rate and progression-free survival of metastatic diseases including breast cancer. Trastuzumab, in combination with various chemotherapeutic drugs, has been evaluated in xenograft models and HER2-overexpressing cell lines. A synergistic or additive interaction for epirubic, docetaxel, doxorubicin, and gemcitabine were observed [15,17]. As a consequence, trastuzumab demonstrated superior clinical results for all stages in HER2-positive breast cancer patients.

The Rous sarcoma virus (v-Src) tyrosine kinase functions as a hub for a vast array of signal transduction pathways, including the Platelet-Derived Growth Factor Receptor (PDGFR), EGFR, and Insulin-like Growth Factor-Receptor (IGF-1R) pathways, to influence cell proliferation, differentiation, motility, and breast cancer survival [18]. Heat Shock Protein 90 (HSP90) is required for the stability and function of several inherently unstable candidate signaling proteins, such as Akt, HER2, Bcr-Abl, c-Kit, EGFR, and PDGFR-α. HSP90 maintains these proteins poised for activation until they are stabilized by conformational changes associated with the formation of signal transduction complexes [19]. In addition, activation of Poly (ADP-ribose) Polymerase 1 (PARP-1), a family of enzymes largely associated with the maintenance of genomic stability, is a component of the immediate cellular response to DNA strand breaks, converting them into an intracellular signal through the poly (ADP-Ribosylation) of nuclear proteins [20]. Several studies have shown that PARP is overexpressed in breast cancer along with the negative estrogen receptor, progesterone receptor, and HER2. BRCA1 and BRCA2 dysfunction is associated with the inhibition of PARP enzymatic activity, resulting in cell cycle arrest and subsequent apoptosis [21].

Angiogenesis is a complex and dynamic process that is essential for tumor development into detectable localized masses and for metastasis. It is regulated by a variety of pro- and anti-angiogenic molecules, such as the VEGF and PDGF protein families and their receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, and PDGFR-β) [22]. Activation of VEGFRs and PDGFRs initiates signaling that plays a central role in angiogenesis and growth. These two signaling pathways represent important targets for breast cancer therapy. Likewise, estrogen along with its receptor stimulates various physiological functions in mammals and are associated with the progression and development of various ailments including cancers (i.e. ovarian, colorectal, breast and endometrial), CVD, and neurodegenerative diseases. Thus far, two Estrogen Receptor (ER) genes have been identified in mammals (i.e. ERα and ERβ) which exhibit similar ligand and DNA-binding features, but distinct function and tissue distribution [23]. Estrogen binds to the ER after entering the cell, separates from heat shock proteins, and undergoes phosphorylation, conformational changes, and dimerization before binding to estrogen response elements. In breast cancer, tamoxifen stimulates cell growth in vitro. Tamoxifen exhibits little affinity for the ER. It is transformed in the liver by cytochrome P450 CY3A4 and CYP26 isoforms into N-desmethyl-4-hydroxy tamoxifen and 4-hydroxy tamoxifen, and shows more efficiency in binding with the ER compared with the parental drug. After attachment, co-repressor proteins (i.e. SMRT and NCoR) regulate various gene functions. The complex requires PA2X2 to induce anticancer effects as a result of the suppression of the pro-proliferative protein, ERBB2. It has been reported that high daily doses of tamoxifen result in the suppression of cancer. However, 80% of the animals in a trial showed no signs of cancer.
of tumor development at small doses over a longer period which was more beneficial compared with long term administration. Long term tamoxifen therapy is superior and may be combined with an aromatase inhibitor. Also, tamoxifen therapy results in fewer serious side effects, although some breast cancer patients are at risk for coronary heart diseases and osteoporosis [24]. Remarkably, in mammary and breast tissues, tamoxifen exhibited anti-estrogenic effects, yet it lowered circulating cholesterol and estrogen in bone and ameliorated hypercholesterolemia [25]. The average dose of tamoxifen is 20 mg/day which does not pose any side effects in breast cancer patients.

**Medicinal Plants with Anticancer Potential from SAARC Countries**

Different species of plants (some worldwide, others strictly native) from SAARC countries have been reported to exhibit activity in breast cancer. **Abras precatorius L.**

*Abras precatorius L.*, which is commonly known as "Indian liquorice", belongs to the *Fabaceae* family. Extracts of the *A. precatorius* leaf inhibit MDA-MB-231 cell growth by inducing apoptosis [26]. Moreover, triterpenoids, abrusalactone A (i), and abrusogenin (ii), which were isolated from the leaves and stem of *Abrus precatorius*, exhibit moderate cytotoxicity against MCF-7 breast cancer cells [27].

**Acrostichum aureum L.**

*Acrostichum aureum L.* (Pteridaceae family), locally known as "Tiger fern," is an evergreen shrub distributed widely throughout Bangladesh, India, and Sri Lanka, primarily in mangrove forests and coastal areas. The methanolic extract of *A. aureum* leaves exhibits selective cytotoxicity against MDA-MB-435S cells [28]. Moreover,
Amoora rohituka which exhibits potent cytotoxic activity against MCF-7 cells [35,36]. It belongs to the domain, and caspases [34].

Aegle marmelos (L.) Corr. Aegle marmelos (L.) Corr., commonly known as Bael, is a deciduous tree of the Rutaceae family. It originated in India, but presently grows in most SAARC countries. The hydroalcoholic extract of the A. marmelos leaves exhibits an anti-proliferative effect on MCF-7 and MDA-MB-231 cell lines [32]. Skimmiarepin A (vii) and C (viii), compounds isolated from the hydroalcoholic extract, inhibited HIF-1 activation by blocking the hypoxia-induced accumulation of HIF-1α protein through hyperphosphorylation and inactivation of translation initiation factor eIF2α and elongation factor eEF2 in T47D cells [33]. In addition, marmelin (ix) was isolated and characterized from the ethyl acetate fraction of A. marmelos and activates apoptosis in epithelial cancer cells through the activation of tumor necrosis factor-α (TNF-α), the TNF receptor-associated death domain, and caspases [34].

Alangium salviifolium Wang. Alangium salviifolium Wang is locally known as "Ankor Kanta" in Bangladesh, "Angol" in India, and "Ruk anguna" in Sri Lanka. The aqueous extract of A. corniculatum shows selective cytotoxicity against MDA-MB-435S cells [28]. Phytochemical studies have shown that embelin (vi) induces MCF-7 breast cancer cell apoptosis in a dose- and time-dependent manner, alters cell mitochondrial membrane potential, and blocks the cell cycle at the G2/M phase. Moreover, embelin promotes the mitochondrial release of cytochrome c by regulating Bax and Bcl-2, resulting in the activation of caspase-3 and -9 [31].

Aegiceras corniculatum L. The mangrove tree or shrub, Aegiceras corniculatum (Myrsinaceae family), is widely distributed in the coastal and estuarine areas of India, Bangladesh, and Sri Lanka. The aqueous extract of A. corniculatum shows selective cytotoxicity against MDA-MB-435S cells [28]. The mangrove tree or shrub, Aegiceras corniculatum (Myrsinaceae family), is widely distributed in the coastal and estuarine areas of India, Bangladesh, and Sri Lanka. The aqueous extract of A. corniculatum shows selective cytotoxicity against MDA-MB-435S cells [28].

Blumea lacer a. Blumea lacer a L. is an annual flowering herb belonging to the Asteraceae family. The methanolic extract of B. lacer a leaves has shown non-selective cytotoxic activity against MDA-MB-435S cells [42]. Studies have demonstrated that the essential oil in its leaves is responsible for the anticancer effect of B. lacer a. Specifically, α-humulene acts by reactive oxygen species-induced cytotoxicity and β-caryophyllene potentiates the anticancer activity of α-humulene [43,44].

Bruguiera gymnorrhiza (L.) Lam.: Bruguiera gymnorrhiza L. is commonly known as "Large-leafed orange mangrove." The methanolic extract of the bark as well as different organic soluble fractions of its leaves exhibited antitumor activity in tumor-bearing mice and these fractions were active against the MDA-MB-435S human cancer cell line. Of the several types of phyto-chemicals, Ent-kaurane diterpenoids (ent-16 β-17 α-dihydroxykaurane) (xiii) significantly reduced Bcl-2 protein and mRNA levels, hTERT mRNA levels, and triggered apoptosis in MCF-7 cells [45].

Daucus carota L. Daucus carota L., commonly known as “carrot,” belongs to the Apiaceae (Umbelliferae) family and is cultivated in most of the world as a vegetable. Carrot oil extract consists mainly of polyphenolpropanoids, monoterpenes, sesquiterpenes, and phenol. In addition to polyphenols, which include flavonoids, carrot oil extract significantly increases cell death and decreases cell proliferation in MCF-7 and MDA-MB-231 cell lines through the Erk signaling pathway [46]. β-Carotene (xv) is the main phytochemical of D. carota. It arrests the cell cycle at the G2/M phase in MCF-7 cells and at the GO/G1 phase in both MDA-MB-231 and MDA-MB-235 cells. It also induces cytotoxicity through a caspase-dependent apoptosis pathway [47].

Dillenia indica L. Dillenia indica L. (Dilleniaceae), known as “Elephant apple,” grows in the moist and evergreen forests of Bangladesh, India, and Nepal. The methanolic extract of the D. indica fruit exhibits significant cytotoxicity against MCF-7 and MDA-MB-231 cells [48]. Betulinic acid (xvi), a pentacyclic triterpenoid isolated from D. indica bark, decreased proliferation and induced apoptosis in estrogen receptor-negative MDA-MB-231 breast cancer cells by downregulating Sp1, Sp3, and Sp4 accompanied by increased zinc finger ZBTB10 expression and decreased microRNA-27a levels. The bark extract also induced cell cycle arrest in the G2/M phase and increased Mst-1 mRNA, which causes inhibition at G2/M through cdc2 phosphorylation [49].

Embelia ribes Burm. F. Embelia ribes Burm. F. (Myrsinaceae) is commonly known as “False black pepper.” The methanolic extract of the E. ribes fruit exhibited a protective effect against multi-mutagenicity, the molecular basis of cancer, and cyclophosphamide-induced genotoxicity in mice [50]. Embelin (vi), a quinonoid compound of E. ribes, induced apoptosis in MCF-7 breast cancer cells in a dose- and time-dependent manner through the induction of apoptosis. This was associated with G2/M phase cell cycle arrest, down regulation of anti-apoptotic (Bcl-2, Bcl-xl, survivin, IAP-1, and IAP-2) and proliferative (cyclin D1) proteins, activation of caspase-3, and PARP cleavage [31].

Lantana camara L. Lantana camara L. is a species of the Verbenaceae family which
Figure 1: Chemical structures of SAARC-originating compounds showing activity against breast cancer.

is commonly known as “Spanish Flag.” The extract obtained from \textit{L. camara} exhibits anticancer activity by inducing apoptosis in MCF-7 cells. Mechanistic studies have revealed a regulatory effect of \textit{L. camara} on the Bcl-2 family proteins including Bid, Bax, Bcl-2, caspase-8, caspase-9, and PARP [51]. Furthermore, Lantadenes A (xvii), B (xviii), and C (xix) and 22β-dimethylacyrloyloxy-24-hydroxy-3-oxoolean-12-en-28-oic acid were isolated from the leaves of \textit{L. camara}. They exhibited weak to moderate cytotoxic activity in MCF-7 cells through the Bcl-2 gene family and also through their binding to the antiapoptotic Bcl-xL protein, which is capable of disrupting the Bcl-xL/Bak association [52,53].

\textbf{Murraya koenigii Linn.}

\textit{Murraya koenigii Linn.}, belongs to the \textit{Rutaceae} family and is commonly known as the “Curry leaf tree.” It is known locally as “Bar Sunga” in Bangladesh, “Mitha neem” in India, and “Karapincha” in Sri Lanka. Non-polar extracts of \textit{M. koenigii} cause a potent cytotoxic effect in various cancers [54]. Ghasemzadeh et al. [55] showed that the leaf extract of \textit{M. koenigii} exhibits significant anticarcinogenic effects in MDA-MB-231 cells, resulting from the presence of various flavonoids, such as quercetin, catechin, epicatechin, naringin, and myricetin. Moreover, various carbazole alkaloids, namely girinimbine (xx) mahanine (xxi), mahanimbicine (xxii), and mahanimbine (xxiii) were isolated from \textit{M. koenigii} and exhibited significant antitumor
activity in MCF-7 cells [56,57].

**Nelumbo nucifera** Wild.

*Nelumbo nucifera* Wild., belongs to the Nelumbonaceae family and is popularly known as “Sacred Lotus”. The hydroalcoholic extract of *N. nucifera* leaves exhibits anticancer effects in MCF-7 cells by causing G0/G1 phase cell cycle, inducing p53 phosphorylation and p21 expression, and downregulating the expression of cyclins and cdk molecules, possibly by the effects of gallic acid, rutin, and quercetin [58,59]. Moreover, neferine (xxiv), a major bisbenzylisoquinoline alkaloid isolated from the embryos of *N. nucifera*, exhibited significantly enhanced ADM cytotoxicity in the multidrug resistant MCF-7/ADM cells and promoted ADR-mediated apoptosis in MCF-7/ADM cells in a dose-dependent manner [60].

**Nyctanthes arbor-tristis** L.

*Nyctanthes arbor-tristis* L., commonly known as “Night Jasmine,” is a member of the Oleaceae family and is locally known as “Sheului” in Bangladesh, “Harsingar” in India, and “Sepalika” in Sri Lanka. The methanolic extract of the dried leaf, fruit, and stem exhibited cytotoxicity against MDA-MB-231 cells [61]. To date, iridoid glycoside Arbortristoside A (xxv) and its synthetic derivatives have shown anticancer activity against MCF-7 and MDA-MB-231 cells through cell cycle arrest and caspase-3-dependent apoptosis [62]. Khanapur et al. [63] reported that the ethanol extract and ethylacetate fractions of *N. arbor-tristis* show potent cytotoxic activity against various breast cancer cells resulting from the presence of flavonoids, phenolics, Crocin-3 (xxvi), and Arborside C (xxvii).

**Physalis minima** L.

*Physalis minima* L. (*Solanaeae*) is commonly known as the “Sun Berry.” The chloroform extract of *P. minima* caused significant growth inhibition of human T47D cells through p53, caspase-3, and c-myc-dependent apoptotic pathways [64]. Moreover, a panel of withanosides was identified from this plant and included physalin F (xxviii), which may act as a chemopreventative agent by triggering apoptosis by activating the caspase-3 and c-myc pathways in T47D cells [65,66].

**Polyalthia longifolia** Benth. & Hook. f.

*Polyalthia longifolia* cv. pendula (*Annonaeeae*) is native to the drier regions of India and is known as “Ashoka.” The chloroform fraction of *P. longifolia* induced apoptosis by increasing sub-G0 DNA fractions, a loss of mitochondrial membrane potential, cytochrome c release, activation of caspase-3 and -9, and PARP cleavage [67]. Clerodane diterpene and (-)-3 α,16 α-dihydroxycleroda-4(18),13(14)-Z-dien-15,16-olide (xxix) were identified from the leaves of *P. longifolia* and exhibited strong apoptotic activity in MCF-7 cells [68].

**Pterocarpus santalinus** L. f.

*Pterocarpus santalinus* L. f., commonly known as “Red sandalwood,” belongs to the Fabaceae family. Phytochemical studies have revealed the presence of neoflavonoids, S-3’-hydroxy-4,4’-dimethoxydalbergione (xxx), and pterolins Hb (xxxii) in *P. santalinus*, and exhibited cytotoxicity in MDA-MB-231 cell lines. Benzofurans, pterolins-B (xxiii), and pterolins-D (xxxiii) was cytotoxic to MCF7 cells [69].

**Solanum nigrum** Linn.

*Solanum nigrum* Linn. (*Solanaceae*) is commonly known as “Black Nightshade.” Crude extracts from *S. nigrum* induced a significant cytotoxic effect against MCF-7 cells by inducing apoptosis and/or autophagocytosis [70]. At high concentrations, crude extract of *S. nigrum* inhibited p-Akt levels and caused cell death resulting from the induction of autophagy and apoptosis in AU565 cells by flavonoids, including gentisic acid, luteolin, apigenin, kaempferol, and m-coumaric acid [71]. A 150-kDa phytyglycoprotein isolated from the plant showed inhibitory effects on the DNA-binding activities of TPA-induced NF-kB and AP-1 as well as an enhancing effect on NO production, which plays an important role in MCF-7 cell cytotoxicity [72,73].

**Future Perspectives and Conclusion**

The identification of plant-derived lead compounds as potential chemotherapeutic agents has enhanced research focused on botanical diversity. Exploration of plant and plant-derived compounds from unexplored areas is expected to provide several new or analogous molecules that exhibit significant therapeutic activity and less toxicity compared with currently available chemotherapeutic drugs. Not only do new, effective therapies with novel mechanisms of action improve our understanding of disease, but they lead to the development of future anticancer drugs. The development of new molecular biological techniques has also facilitated the identification of individual components in key cell systems, increased our understanding of cancer therapy, and provided a basis for elucidating the underlying mechanisms of many drugs. Furthermore, they have enabled scientists to produce individual proteins or related human homologs for structural study and for use in the screening of natural compounds. Similarly, developments in instrumentation, such as high-throughput screening, has facilitated the analysis of a large number of compounds for anticancer activity.

The geographic and environmental variation among the SAARC countries provides rich plant diversity. However, because of a lack of advanced research facilities and funds, the development of natural anticancer agents has been hindered. The present review focused on research trends using breast cancer cell lines, such as MCF-7, MDA-MB-231, MDA-MB-235, MDA-MB-435S, T47D, and AU565. We also summarized the results of natural products in sensitive and resistant breast cancer cells since overcoming drug resistance is a major limitation to the successful treatment of breast cancer. This brief review examined unique plant-derived molecules from SAARC and their mechanisms of action against breast cancer. As the interface between chemistry and biology narrows and the demand for cost-effective medication and biological agents from sustainable resources increases, the study of plant extracts and their active compounds for anticancer properties will only increase.

Synergistic effects can maximize the therapeutic efficacy of anticancer drugs [74]. In a recent study, we demonstrated the optimum effect of three polyphenol compounds by establishing combination indices [75]. This strategy may be applied to breast cancer studies by (1) identify synergistic effects between compounds in the plant itself, (2) comparing the synergistic effects between plant-derived natural products and compounds or existing anticancer drugs, and (3) comparing natural products derived from plants with marine or other natural products. Natural anti-breast cancer substances with excellent efficacy may be evaluated for synergistic activity through various approaches such as in silico prediction, docking simulation, quantitative structure-activity relationship, and prediction of activity spectra for substances. When active compounds from natural products or foods exert a synergistic effect on a molecular target in breast cancer, we expect to observe robust anticancer effects.

---

**References**


---

Acknowledgment

Md Badrul Alam and Hee-Jeong Choi are supported by BK21 Plus Creative Innovative Group for Leading Future Functional Food Industry, Kyungpook National University.

Funding

This study was supported by the National Research Foundation of Korea (NRF) grant, funded by the Ministry of Science and ICT (2020R1A2C2011495).

References


